{"name":"European Organisation for Research and Treatment of Cancer - EORTC","slug":"european-organisation-for-research-and-treatment-of-cancer-eortc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-12-01","label":"methoxypsoralen Phase 3 readout (Bronchiolitis Obliterans Syndrome (BOS))","drug":"methoxypsoralen","drugSlug":"methoxypsoralen","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":11,"colorKey":"oncology","drugs":[{"name":"FLOT","genericName":"FLOT","slug":"flot","indication":"Metastatic or locally advanced gastric cancer","status":"marketed"},{"name":"ISIS 3521","genericName":"ISIS 3521","slug":"isis-3521","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"177Lu-PSMA-617","genericName":"177Lu-PSMA-617","slug":"177lu-psma-617","indication":"Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression","status":"phase_3"},{"name":"ABVD q4 weeks","genericName":"ABVD q4 weeks","slug":"abvd-q4-weeks","indication":"Hodgkin lymphoma","status":"phase_3"},{"name":"BEACOPP escalated q3 weeks","genericName":"BEACOPP escalated q3 weeks","slug":"beacopp-escalated-q3-weeks","indication":"Hodgkin lymphoma, advanced stages (Phase 3 evaluation)","status":"phase_3"},{"name":"GM2-KLH vaccine","genericName":"GM2-KLH vaccine","slug":"gm2-klh-vaccine","indication":"Melanoma (adjuvant setting)","status":"phase_3"},{"name":"Pertuzumab + trastuzumab","genericName":"Pertuzumab + trastuzumab","slug":"pertuzumab-trastuzumab","indication":"HER2-positive metastatic breast cancer","status":"marketed"},{"name":"Ra223","genericName":"Ra223","slug":"ra223","indication":"Castration-resistant prostate cancer with symptomatic bone metastases","status":"phase_3"},{"name":"cMAB","genericName":"cMAB","slug":"cmab","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"iMAB","genericName":"iMAB","slug":"imab","indication":"Cancer (specific indication under phase 3 evaluation by EORTC)","status":"phase_3"},{"name":"monoclonal antibody BEC2","genericName":"monoclonal antibody BEC2","slug":"monoclonal-antibody-bec2","indication":"Melanoma (advanced or metastatic)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"approved GnRH agonist","genericName":"approved GnRH agonist","slug":"approved-gnrh-agonist","indication":"Other","status":"phase_3"},{"name":"methoxypsoralen","genericName":"methoxypsoralen","slug":"methoxypsoralen","indication":"Other","status":"discontinued"}]}],"pipeline":[{"name":"FLOT","genericName":"FLOT","slug":"flot","phase":"marketed","mechanism":"FLOT is a chemotherapy regimen combining fluorouracil, leucovorin, oxaliplatin, and docetaxel to inhibit DNA synthesis and microtubule formation, killing rapidly dividing cancer cells.","indications":["Metastatic or locally advanced gastric cancer","Gastroesophageal junction adenocarcinoma","Perioperative treatment of resectable gastric cancer"],"catalyst":""},{"name":"ISIS 3521","genericName":"ISIS 3521","slug":"isis-3521","phase":"phase_3","mechanism":"ISIS 3521 is an antisense oligonucleotide that inhibits protein kinase C-alpha (PKC-alpha) expression to suppress cancer cell proliferation and survival.","indications":["Non-small cell lung cancer","Ovarian cancer","Colorectal cancer"],"catalyst":""},{"name":"177Lu-PSMA-617","genericName":"177Lu-PSMA-617","slug":"177lu-psma-617","phase":"phase_3","mechanism":"177Lu-PSMA-617 is a radioligand that binds to prostate-specific membrane antigen (PSMA) on cancer cells and delivers targeted radiation therapy to kill PSMA-expressing tumors.","indications":["Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression"],"catalyst":""},{"name":"ABVD q4 weeks","genericName":"ABVD q4 weeks","slug":"abvd-q4-weeks","phase":"phase_3","mechanism":"ABVD is a combination chemotherapy regimen that uses four cytotoxic agents to kill rapidly dividing cancer cells through multiple mechanisms including DNA alkylation, topoisomerase inhibition, and microtubule disruption.","indications":["Hodgkin lymphoma","Non-Hodgkin lymphoma"],"catalyst":""},{"name":"BEACOPP escalated q3 weeks","genericName":"BEACOPP escalated q3 weeks","slug":"beacopp-escalated-q3-weeks","phase":"phase_3","mechanism":"BEACOPP escalated is a multi-drug chemotherapy regimen that combines bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone at escalated doses to kill rapidly dividing cancer cells.","indications":["Hodgkin lymphoma, advanced stages (Phase 3 evaluation)"],"catalyst":""},{"name":"GM2-KLH vaccine","genericName":"GM2-KLH vaccine","slug":"gm2-klh-vaccine","phase":"phase_3","mechanism":"GM2-KLH vaccine stimulates the immune system to recognize and attack cancer cells expressing the GM2 ganglioside antigen on their surface.","indications":["Melanoma (adjuvant setting)","Ovarian cancer"],"catalyst":""},{"name":"Pertuzumab + trastuzumab","genericName":"Pertuzumab + trastuzumab","slug":"pertuzumab-trastuzumab","phase":"marketed","mechanism":"Pertuzumab and trastuzumab are monoclonal antibodies that block HER2 signaling by binding to different epitopes on the HER2 receptor, preventing ligand-induced dimerization and receptor activation.","indications":["HER2-positive metastatic breast cancer","HER2-positive early-stage breast cancer (neoadjuvant and adjuvant settings)"],"catalyst":""},{"name":"Ra223","genericName":"Ra223","slug":"ra223","phase":"phase_3","mechanism":"Ra223 is an alpha-emitting radiopharmaceutical that targets bone metastases and delivers localized radiation to kill cancer cells.","indications":["Castration-resistant prostate cancer with symptomatic bone metastases"],"catalyst":""},{"name":"approved GnRH agonist","genericName":"approved GnRH agonist","slug":"approved-gnrh-agonist","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"cMAB","genericName":"cMAB","slug":"cmab","phase":"phase_3","mechanism":"cMAB is a monoclonal antibody targeting the PD-1 receptor.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive","Metastatic melanoma"],"catalyst":""},{"name":"iMAB","genericName":"iMAB","slug":"imab","phase":"phase_3","mechanism":"iMAB is an investigational immunomodulatory antibody designed to enhance anti-tumor immune responses.","indications":["Cancer (specific indication under phase 3 evaluation by EORTC)"],"catalyst":""},{"name":"methoxypsoralen","genericName":"methoxypsoralen","slug":"methoxypsoralen","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"monoclonal antibody BEC2","genericName":"monoclonal antibody BEC2","slug":"monoclonal-antibody-bec2","phase":"phase_3","mechanism":"BEC2 is a monoclonal antibody that targets GD3 ganglioside on tumor cell surfaces to trigger immune-mediated destruction of cancer cells.","indications":["Melanoma (advanced or metastatic)","Small cell lung cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOQndHMHhZaGl3cnhVYkVveGdXUG5nTzlQVDAtd3Jwazk0M2lnT2c1U1ptQmk1dm1ydFJ6Y3VrRWZHaFMxanFwcXRDb25LdDI2RjU3WDRIQ2RiZlozZDk0Nk1ab1ZtcWZkc1p1anlIUjJHaUYtT0hpWWpDME5uY3FQWktYT1Y1NVYydHhzYmZGM2dwd1pKUUhMV0lraHJZTDhQcjdpX1I2MXFLOUVVODQzZEtmSWlVZHBveDNIcU03M1E?oc=5","date":"2026-03-20","type":"trial","source":"Il Sole 24 ORE","summary":"Cancer, clinical trials launched in Europe halved in 10 years and China takes the scene - Il Sole 24 ORE","headline":"Cancer, clinical trials launched in Europe halved in 10 years and China takes the scene - Il Sole 24 ORE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxOZzZ0S1M0M1dVN1NHU3cwT0s1WEtmRVplSVZwV2xyVXoxVk8ycUtSZ05Rb2pEaGhPNHN6aGNncVZJdTBIQnZkWGV0RWJ5ZDRLYVZvRUl0UUNyR21OVjQ5SGllSmh0UVJSTllMZ0hNWkVwUVhkc2dvSWdmZkZZX05nUnpCMXNFSW4zczZoNnhoUW1GRTZ1UEc4T21BYWJPMlZDeDZraUl3MDJzdEo0UkwtZS1OejNINVpvdXZSWDV5TGVCS0p6cVZtdjJGXzNlUExaMG51cVJKelVLNHA1NlhxcGNHanNYeVdjWkVTekNEQTFCekFjNjZmbHhGWEtkMmM5amE5SzFDXzlkRHM?oc=5","date":"2026-02-27","type":"pipeline","source":"GlobeNewswire","summary":"ZUSDURI™ Achieves Durable Complete Responses Across EORTC - GlobeNewswire","headline":"ZUSDURI™ Achieves Durable Complete Responses Across EORTC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOYU12YUdsRG9NRUJ6SFAxeXlObExHWjJPWDRyVU1Wc1A0M1czbmxaUFJZak0ydWt5UHA1UldmZk9kZmlwUlQ2SS1KU21OV2xNZldNcUFjUmFUVzdSVUxSUTBWdWdueWdQLWNSdU16cE96YWdaMVNSTjdXZS1WZGVCNkNJYVVDQkd0WG93UGpVYkZ5WHdtOWZVTkdydUxmVlZPX2tWcUUtVDR4Q1l6RS1QTFY3bTRNT3pPeFE?oc=5","date":"2026-02-27","type":"trial","source":"Stock Titan","summary":"Bladder cancer trial: ZUSDURI keeps many patients recurrence-free for 2 years - Stock Titan","headline":"Bladder cancer trial: ZUSDURI keeps many patients recurrence-free for 2 years","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE10S3VwN2VoTEgxTXRCbVFxVEw2Zk1FZUR0R21SQnIxaTZjVk1KaUZfX29uVUlEMG5YcUYyb1Vxa09MY2NFZmdlY0ktcExCazVPT1pkRUI2MjNQb0pOQ3dNQmJR?oc=5","date":"2026-01-09","type":"pipeline","source":"Oncodaily","summary":"Denis Lacombe Recognized Among The 100 Most Influential CEOs in Oncology in 2025 - Oncodaily","headline":"Denis Lacombe Recognized Among The 100 Most Influential CEOs in Oncology in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE9uSDlYWEpJYXdhQ2drQzhYOHJLd0twQ2Y1WE9rdGlISEk2ZngwWG9ETDNGMHpKQ2Utb0tVcGFNTGVvdEt6VjN1aWE0YWlMaThtd3l2TVdYQ3Z0cEw1RDJFZHlkZnU2WEZUMTdJdGd3ZHFzNUk?oc=5","date":"2025-10-15","type":"trial","source":"Taylor & Francis Online","summary":"HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors: Future Oncology: Vol 21, No 25 - Taylor & Francis Online","headline":"HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors: F","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-13","type":"trial","source":"prnewswire.com","summary":"Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Confer","headline":"Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, wi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxNdTJzYVJvOWJ2eGV0NGMtdTdKMkpPSExJRVNtWGJ4LW85LWozYmc3OUhLbXVlMUNtOHItWmt2WHZIMzdqMi1Ib2V6QTJKc2NFQ0x4SFVIeXNCdnNkbUhGTWF1dTk2YVM2Vm9mSWl5LU93aG02THl1RjhMOU5OaFkwVHVaTzAtS3h6WWFHYS1XMEhqOXh5cGNFcGRPTE51UUVkdmFIUUQzTFpqNVdiaVF0YXRSWHR1TEhYMkFrOTlmOHVIVzhpYWRxcEg0aFBMY2tkeXI4RmNCLW1CblNCdGFWN0JtdE5zN1B5VHVBQUlTcWdkVFdFQmhEUXQxT19qYTZmTTBDeWNxTFRQaFdlTFBfVWZJTEdtMHVhejFz?oc=5","date":"2025-06-12","type":"pipeline","source":"European Medical Journal","summary":"Advancements in Hydrogel-Based Therapies as Non-surgical Alternatives for Urothelial Carcinoma: Ongoing Research and New Insights - European Medical Journal","headline":"Advancements in Hydrogel-Based Therapies as Non-surgical Alternatives for Urothelial Carcinoma: Ongoing Research and New","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPQXNKY05rQXVrYWpqZU55R3R2Q09tQzRqNXN4dzlrYUhLUXFxR0NzV016NTJpNjBPNmh1VU1EZTF0YzNZdnhuakJsQUxFRmdSVnVadDJoNlBjY3UzNjVsbHJxMmxmRnVmaDZnUnBtRjNUYVdpR3FqNm9ZWEFfbUw3T2lGZTBncHVUTUFz?oc=5","date":"2025-05-01","type":"trial","source":"The Lancet","summary":"Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of Cancer - The Lancet","headline":"Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNLUY1c2QzelFqYmlSTWZYTXlqS3JlNVFia290VmRwWlo3MXVlYklpOGI2c0ZTU0RNNnhRWXRRY2EzckVyZ1JOTDFoSVBvanhrbk5CS0VObExXLTBEcmdIRlFabTFvRHNaMXUwVXJmblgxSEJMMHk3a1kzNWRmd2hITF9HblBET0V1VHpsa1RaQXV3ellfUE5kMDEybw?oc=5","date":"2024-10-28","type":"pipeline","source":"University of Miami","summary":"Sylvester Physician-Scientists Find New Target for Cancer Treatment - University of Miami","headline":"Sylvester Physician-Scientists Find New Target for Cancer Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNbEhRcU1iVmtueVdHRlNoaHg5UExTdHhkQ1hySXZGemUzQjR0Nk1jX2xaMmZVRC1DdW84V1hPTHhnZjJyeVB2Y1BKZ2d2dkYtRkFZSGJzWnNPcnVuekZtOTBnMEc4YkNzTmVGRjBwQk5mZFBDNXFCOEtwb2pkU001SElFSndBNkZlNExrX096eXg0UjQ?oc=5","date":"2024-02-06","type":"trial","source":"Frontiers","summary":"How do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of Cancer - Frontier","headline":"How do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international sur","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBVRVdpM181el9HUVdWRi1OczZENnVHR3hvcGlyMnRqMUE0U1E1QkpTOEtaN2RFX05ldm1HR2hFbU9FOFpoMnJUMXBZTkJ4aWgtTmFPZ3F6YTFBRDREZXlN?oc=5","date":"2023-05-16","type":"pipeline","source":"Nature","summary":"Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development - Nature","headline":"Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPVFMtSTJfRzlERlJjN1JMdU9vbFlwclRLNGh2VXFyMy15UE1sNGFGUDdkd3J3WUdoQ3ZlZ21JWkFxMVppTlBqNGEtSTBHZ2UyU0FCTE4td3o3VlRHbmUwdXdSTjBOYkVyUjI1M2g3bW9zUTFtTi1XR2FZWVJjRGJnTDhUbWd5RWxDcGZIeG1LYWQyYjBVSGpxMVZnQzZ4c2JXblNPSjdxQkFleGtRUF9QVGJvX1dEQ1Rpb0ZVaUVZS2dGdm8?oc=5","date":"2020-08-18","type":"trial","source":"appliedclinicaltrialsonline.com","summary":"Project Management Platform in an Academic Environment: The EORTC'S Promising Experience - appliedclinicaltrialsonline.com","headline":"Project Management Platform in an Academic Environment: The EORTC'S Promising Experience","sentiment":"neutral"}],"patents":[],"drugCount":13,"phaseCounts":{"marketed":2,"phase_3":10,"discontinued":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}